Compare FedEx Corporation (FDX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? FedEx Corporation trades at $325.86 (market cap $76.28B), while State Street SPDR S&P Biotech ETF trades at $158.96. The key difference: FedEx Corporation pays a 1.51% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| FDX | XBI | |
|---|---|---|
Market Cap | $76.28B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $338.75 | $164.28 |
52-Week Low | $180.51 | $86.92 |
Enterprise Value | $105.91B | — |
Dividend Yield | 1.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $325.53, up 0.14% on the day, with a bullish technical signal and strong analyst backing. Recent earnings beats in Q4 2025 and Q1 2026, with EPS of $5.25 and $6.31 respectively against expectations, highlight operational strength. The company's Network 2.0 initiative aims for $2 billion in annual savings, supporting margin improvement. Valuation ratios like P/E of 17.38 and P/S of 0.81 appear reasonable relative to historical levels.
Outlook is positive with a consensus price target of $360.27, implying 11% upside, driven by cost-cutting and premium revenue shifts. Risks include softer freight demand and debt levels, but institutional buying and bullish sentiment suggest confidence in FedEx's execution amid economic uncertainties.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
